O	0	1	A
O	2	12	Randomized
O	13	23	Controlled
O	24	29	Trial
O	30	32	of
O	33	41	Exercise
O	42	44	to
O	45	52	Prevent
B-condition	53	57	Bone
I-condition	58	62	Loss
O	63	65	in
O	66	79	Premenopausal
O	80	85	Women
O	86	90	with
O	91	97	Breast
O	98	104	Cancer
O	104	105	.

O	106	116	Background
O	116	117	/
O	117	129	Introduction
O	129	130	/
O	130	139	Objective
O	139	140	:
O	141	154	Premenopausal
O	155	160	women
O	161	168	treated
O	169	172	for
O	173	179	breast
O	180	186	cancer
O	187	190	are
O	191	193	at
O	194	198	high
O	199	203	risk
O	204	207	for
O	208	212	bone
O	213	217	loss
O	217	218	.

O	219	223	This
O	224	229	trial
O	230	238	examined
O	239	242	the
O	243	250	effects
O	251	253	of
O	254	255	a
O	256	257	1
O	257	258	-
O	258	262	year
B-intervention	263	271	combined
I-intervention	272	279	aerobic
I-intervention	280	283	and
I-intervention	284	294	resistance
I-intervention	295	303	exercise
O	304	311	program
O	312	314	on
O	315	319	bone
O	320	327	mineral
O	328	335	density
O	336	337	(
O	337	340	BMD
O	340	341	)
O	342	344	in
O	345	350	women
O	351	358	treated
O	359	362	for
O	363	376	premenopausal
O	377	383	breast
O	384	390	cancer
O	390	391	.

B-eligibility	392	405	Premenopausal
I-eligibility	406	411	women
O	412	413	(
O	413	414	n
O	415	416	=
B-total-participants	417	420	206
O	420	421	)
O	422	425	age
B-age	426	427	≤
I-age	428	430	55
I-age	431	436	years
B-eligibility	437	439	at
I-eligibility	440	446	cancer
I-eligibility	447	456	diagnosis
I-eligibility	457	460	who
I-eligibility	461	465	were
I-eligibility	466	472	within
I-eligibility	473	476	two
I-eligibility	477	482	years
I-eligibility	483	485	of
I-eligibility	486	495	receiving
I-eligibility	496	504	adjuvant
I-eligibility	505	517	chemotherapy
O	518	522	were
O	523	533	randomized
O	534	536	to
O	537	538	a
O	539	541	12
O	541	542	-
O	542	547	month
O	548	556	exercise
O	557	564	program
O	565	567	or
O	568	569	a
B-control	570	577	control
I-control	578	583	group
O	583	584	.

O	585	588	BMD
O	589	592	was
O	593	601	measured
O	602	604	by
O	605	609	dual
O	609	610	-
O	610	616	energy
O	617	618	X
O	618	619	-
O	619	622	ray
O	623	637	absorptiometry
O	638	640	at
O	641	649	baseline
O	650	653	and
O	654	659	after
O	660	661	1
O	662	666	year
O	666	667	;
O	668	673	blood
O	674	677	was
O	678	683	drawn
O	684	687	for
O	688	696	skeletal
O	697	704	markers
O	704	705	.

O	706	712	Change
O	713	717	from
O	718	726	baseline
O	727	729	to
O	730	733	end
O	734	736	of
O	737	742	study
O	743	746	was
O	747	755	compared
O	756	762	within
O	763	766	and
O	767	774	between
O	775	784	treatment
O	785	791	groups
O	792	797	using
O	798	804	paired
O	805	808	and
O	809	817	unpaired
O	818	819	t
O	819	820	-
O	820	825	tests
O	825	826	.

B-outcome	827	833	Lumbar
I-outcome	834	839	spine
I-outcome	840	843	BMD
O	844	852	declined
O	853	855	in
O	856	860	both
O	861	870	treatment
O	871	877	groups
O	878	882	with
O	883	885	no
O	886	897	significant
O	898	908	difference
O	909	916	between
O	917	926	treatment
O	927	933	groups
O	934	935	(
B-iv-cont-mean	935	936	-
I-iv-cont-mean	936	937	0
I-iv-cont-mean	937	938	.
I-iv-cont-mean	938	941	008
O	942	943	±
B-iv-cont-mean	944	945	0
I-iv-cont-mean	945	946	.
I-iv-cont-mean	946	949	003
I-iv-cont-mean	950	951	g
I-iv-cont-mean	951	952	/
I-iv-cont-mean	952	955	cm2
O	956	964	exercise
O	965	967	vs
O	967	968	.
B-cv-cont-mean	969	970	-
I-cv-cont-mean	970	971	0
I-cv-cont-mean	971	972	.
I-cv-cont-mean	972	975	014
O	976	977	±
B-cv-cont-sd	978	979	0
I-cv-cont-sd	979	980	.
I-cv-cont-sd	980	983	003
I-cv-cont-sd	984	985	g
I-cv-cont-sd	985	986	/
I-cv-cont-sd	986	989	cm2
O	990	997	control
O	997	998	,
O	999	1000	p
O	1001	1002	=
O	1003	1004	0
O	1004	1005	.
O	1005	1007	24
O	1007	1008	)
O	1008	1009	.

O	1010	1017	However
O	1017	1018	,
O	1019	1024	among
O	1025	1028	the
O	1029	1034	women
O	1035	1038	who
O	1039	1042	did
O	1043	1046	not
O	1047	1051	lose
O	1052	1056	lean
O	1057	1061	mass
O	1062	1068	during
O	1069	1072	the
O	1073	1078	study
O	1079	1080	(
O	1080	1081	n
O	1082	1083	=
B-total-participants	1084	1087	100
O	1087	1088	,
B-control-participants	1089	1091	54
O	1092	1099	control
O	1099	1100	,
B-intervention-participants	1101	1103	46
O	1104	1112	exercise
O	1112	1113	)
O	1113	1114	,
O	1115	1118	the
O	1119	1127	exercise
O	1128	1140	intervention
O	1141	1150	prevented
B-outcome	1151	1157	lumbar
I-outcome	1158	1163	spine
I-outcome	1164	1168	bone
I-outcome	1169	1173	loss
O	1174	1175	(
B-iv-cont-mean	1175	1176	0
I-iv-cont-mean	1176	1177	.
I-iv-cont-mean	1177	1180	001
O	1181	1182	±
B-iv-cont-sd	1183	1184	0
I-iv-cont-sd	1184	1185	.
I-iv-cont-sd	1185	1188	005
I-iv-cont-sd	1189	1190	g
I-iv-cont-sd	1190	1191	/
I-iv-cont-sd	1191	1194	cm2
O	1195	1204	treatment
O	1205	1210	group
O	1211	1213	vs
O	1213	1214	.
B-cv-cont-mean	1215	1216	-
I-cv-cont-mean	1216	1217	0
I-cv-cont-mean	1217	1218	.
I-cv-cont-mean	1218	1221	014
O	1222	1223	±
B-cv-cont-sd	1224	1225	0
I-cv-cont-sd	1225	1226	.
I-cv-cont-sd	1226	1229	005
I-cv-cont-sd	1230	1231	g
I-cv-cont-sd	1231	1232	/
I-cv-cont-sd	1232	1235	cm2
O	1236	1243	control
O	1244	1249	group
O	1249	1250	,
O	1251	1252	p
O	1253	1254	=
O	1255	1256	0
O	1256	1257	.
O	1257	1259	03
O	1259	1260	)
O	1260	1261	.

B-outcome	1262	1266	Bone
I-outcome	1267	1275	turnover
I-outcome	1276	1283	markers
I-outcome	1284	1293	decreased
O	1294	1307	significantly
O	1308	1310	in
O	1311	1315	both
O	1316	1322	groups
O	1323	1327	with
O	1328	1330	no
O	1331	1342	differences
O	1343	1350	between
O	1351	1357	groups
O	1357	1358	.

O	1359	1364	Among
O	1365	1370	women
O	1371	1374	who
O	1375	1385	maintained
O	1386	1390	lean
O	1391	1395	mass
O	1395	1396	,
O	1397	1400	our
O	1401	1409	exercise
O	1410	1422	intervention
O	1423	1432	prevented
O	1433	1437	bone
O	1438	1442	loss
O	1442	1443	;
O	1444	1451	however
O	1451	1452	,
O	1453	1456	our
O	1457	1469	intervention
O	1470	1473	did
O	1474	1477	not
O	1478	1485	prevent
O	1486	1490	bone
O	1491	1495	loss
O	1496	1501	among
O	1502	1507	women
O	1508	1511	who
O	1512	1516	lost
O	1517	1523	muscle
O	1524	1528	mass
O	1528	1529	.

O	1530	1540	Additional
O	1541	1554	investigation
O	1555	1559	into
O	1560	1568	exercise
O	1569	1577	regimens
O	1578	1582	that
O	1583	1586	can
O	1587	1594	prevent
O	1595	1599	both
O	1600	1604	bone
O	1605	1608	and
O	1609	1615	muscle
O	1616	1620	loss
O	1621	1624	may
O	1625	1629	help
O	1630	1637	prevent
O	1638	1642	long
O	1642	1643	-
O	1643	1647	term
O	1648	1660	consequences
O	1661	1663	of
O	1664	1677	premenopausal
O	1678	1684	breast
O	1685	1691	cancer
O	1692	1701	treatment
O	1701	1702	.
